Penn Pharma Invests £3million in Additional Manufacturing Capacity
News Jul 18, 2013
This investment is in addition to the £14 million recently invested in a solid dose contained manufacturing facility to handle potent active pharmaceutical ingredients.
Penn Pharma Chief Executive Officer, Richard Yarwood, commented: “We are making this additional significant investment to meet our growing customer demands. It is fuelled by our demonstrated ability to provide pragmatic and timely solutions for their needs. At a time when many businesses are struggling we are continuing to grow the Penn business and our recent investments give us the platform to provide even better services to our customers”.
The new £3million investment follows the recent completion of Penn Pharma’s new 15,000 sq ft site for the clinical and commercial manufacture of tablets and capsules. The new industry-leading facility will deliver both the clinical and commercial contained manufacturing needs of its clients.
Penn Pharma Chief Operating Officer, Mark Dean-Netscher, also commented: “Again, we at Penn are demonstrating our commitment to our customers and our growth as a business. This additional investment will ensure we deliver to our customers and exceed expectations”.
Penn Pharma has been providing pharmaceutical services for over 30 years and employs 275 staff on its two sites in South Wales. It has twice won the prestigious Queen’s Award for Enterprise in recognition of the work it provides to Export markets including the USA and Japan.
UT Southwestern researchers have succeeded in neutralizing what they believe is a primary factor in late-onset Alzheimer’s disease, opening the door to development of a drug that could be administered before age 40, and taken for life, to potentially prevent the disease in 50 to 80 percent of at-risk adults.READ MORE